Skip to main content
RemeGen Co., Ltd. logo

RemeGen Co., Ltd. — Investor Relations & Filings

Ticker · 9995 ISIN · CNE1000048G6 LEI · 300300M9HCX4TFAD4I10 HKEX Manufacturing
Open in API
Filings indexed 1,625 across all filing types
Latest filing 2021-10-21 Regulatory Filings
Country CN China
Listing HKEX 9995

About RemeGen Co., Ltd.

http://www.remegen.com

RemeGen Co., Ltd. is a biopharmaceutical company dedicated to the discovery, development, production, and commercialization of innovative biological drugs. The company focuses on creating first-in-class and best-in-class therapeutics to address significant unmet clinical needs, particularly in the critical therapeutic areas of autoimmune diseases, oncology, and ophthalmology. RemeGen utilizes proprietary technology platforms capable of discovering, screening, and developing new molecules and efficiently optimizing production processes. Its pipeline includes a series of innovative biologics, such as Telitacicept, and features 8 clinical pipelines, over 40 clinical trials, and more than 600 patent applications, demonstrating a strong commitment to R&D and innovation in biopharmaceuticals.

Recent filings

Filing Released Lang Actions
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is a placeholder message from the Hong Kong Exchanges and Clearing Limited stating that the requested document has been removed by the issuer. Since it does not contain any substantive financial or corporate information and serves as a system-generated notice regarding a missing filing, it falls under the general regulatory announcement category.
2021-10-21 English
CONNECTED TRANSACTION - LIGHT CURRENT ENGINEERING AGREEMENT
Regulatory Filings Classification · 95% confidence The document is an announcement by Overseas Chinese Town (Asia) Holdings Limited regarding a connected transaction involving a Light Current Engineering Agreement. It details the terms, parties involved, service fees, and regulatory implications under the Hong Kong Stock Exchange Listing Rules, specifically Chapter 14A concerning connected transactions. The document is an announcement of a specific transaction rather than a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial analysis but focuses on the disclosure of a connected transaction as required by listing rules. Therefore, it fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2021-10-21 English
REVISION OF ANNUAL CAPS UNDER THE MATERIALS PURCHASE FRAMEWORK AGREEMENT AND THE GENERAL SERVICES FRAMEWORK AGREEMENT
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the revision of annual caps under two framework agreements (Materials Purchase Framework Agreement and General Services Framework Agreement) related to continuing connected transactions. It discusses historical transaction amounts, revised caps for upcoming years, and the rationale behind these revisions. The document is structured as a formal announcement with references to the Listing Rules and connected transactions, typical of regulatory disclosures for ongoing contractual arrangements. It does not contain full financial statements or comprehensive financial performance data, nor is it a transcript, proxy statement, or remuneration report. The content focuses on updates to transaction limits under existing agreements, which aligns with capital or financing updates. Therefore, the document is best classified as a Capital/Financing Update (CAP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2021-10-18 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2021
Regulatory Filings Classification · 95% confidence The document is a detailed monthly return regarding movements in securities, specifically focusing on authorized/registered share capital and issued shares for RemeGen Co., Ltd. It includes tables of share capital balances, confirmations related to share issuance, and compliance with listing rules on the Stock Exchange of Hong Kong. There is no indication of it being an annual or quarterly financial report, audit report, earnings release, or any other financial statement. Instead, it is a regulatory filing related to share capital and securities movements, submitted to the Hong Kong Exchanges and Clearing Limited as per listing rules. The document length (8174 characters) and content indicate it is a formal regulatory submission rather than a brief announcement or a report publication notice. Therefore, the most appropriate classification is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2021-10-07 English
Monthly Return of Equity Issuer on Movement in Securities for the month ended 30 September 2021
Regulatory Filings Classification · 95% confidence The document is a monthly return report detailing movements in authorised and issued shares of Overseas Chinese Town (Asia) Holdings Limited, including confirmations related to securities issued. It references compliance with the Stock Exchange of Hong Kong Listing Rules and includes detailed share capital and share movement information. The document is not a full financial report, earnings release, or management discussion, but rather a regulatory submission about share capital and securities movements. It fits the category of a Regulatory Filing (RNS) as it is a compliance document submitted to the exchange and does not contain financial statements or detailed financial analysis. The document length (6226 characters) and content confirm it is not a brief announcement or a report publication notice but a formal regulatory filing.
2021-09-30 English
Notification Letter and Request Form to Non-Registered Holders - Notice of Publication of 2021 Interim Report ("Current Corporate Communications")
Report Publication Announcement Classification · 95% confidence The document is a notification letter from RemeGen Co., Ltd. dated 24 September 2021, informing non-registered shareholders about the publication of the company's 2021 Interim Report. It provides instructions on how to access the report online and how to request a printed version. The document does not contain the actual interim report or substantive financial data but serves as a communication to shareholders about the availability of the report. It also includes a request form for shareholders to choose their preferred format for receiving corporate communications. Given the document's nature as a notification of report publication rather than the report itself, and its length being under 7,000 characters, it fits the criteria for a Report Publication Announcement (RPA).
2021-09-23 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.